Affiliation:
1. Dermatology Department APHP, Henri Mondor Hospital Créteil France
2. EA7379 EpidermE, Univ Paris Est Créteil EpidermE Créteil France
3. Reference Center for Toxic Bullous Diseases and Severe Drug Reactions Créteil France
4. Department of Pharmacy AP‐HP, Hôpital Henri‐Mondor Créteil France
Abstract
AbstractBackgroundPatch tests (PTs) are recommended to identify the culprit drug in non‐immediate cutaneous adverse drug reactions (NICADRs). We recently reported that, in patients with NICADRs, a unique reading of PTs at day (D)2 compared with an additional second late reading at D4 missed almost half (45.3%) of the positive PTs.ObjectivesTo assess the change in sensitivity of the PT reading on D4 compared with the reading on D3.MethodsWe performed a retrospective (July 2020–June 2023) monocentric study of patients who had PTs with two readings for a NICADR. We compared reading on D3 and the second reading on D4 for the suspected drug (primary outcome) and for the related drugs tested simultaneously (secondary outcome).ResultsDuring the study period, 249 patients underwent patch testing with D3 and D4 readings. Regarding the primary outcome, the first reading at D3 was positive for 13.7% of patients, and the reading at D4 for 24.9% of patients (p < 0.0001). Regarding the secondary outcome, only 9.6% of patients had all their positive PT at D3 compared with 24.9% of patients at D4 (p < 0.0001). Considering the evaluated drug classes, no statistical difference was observed. However, we highlight that D3 reading detected all positive carbamazepine PTs (n = 3) while positive clindamycin PTs (n = 4) were identified only with the help of the second reading on D4.ConclusionThis study showed that, an additional D4 reading compared with a single D3 reading enhanced the sensitivity of PTs to identify culprit drugs and related. Further studies should replicate these findings and evaluate the medico‐economic balance and safety of a single reading of PTs on D4.